| abstract |
This invention relates to sulfamides of the defined formula I, which are metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods for the preparation of these compounds. These are compounds of formula l in which R1 and R2 are independently selected from H, alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, or R1 and R2 together with the carbon atom to which they are attached form a carbocycle or a heterocycle; R3 signifies H, alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or R3 together with R1 or R2 and the atoms to which they are attached form a heterocycloamino group; R10 is NR11OR12; R20 and R21 are independently selected from H, alkyl, heteroalkyl, cycloalkyl, aralkyl, aralkenyl, or R20 and R21 together with the N atom to which they are attached form an optionally substituted tetrahydropyridine or hexahydroaxepine ring, or any one together with R3 form an alkylene group; and its pharmaceutically acceptable salts, prodrugs, individual isomers, and mixtures of isomers. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, and a pharmaceutically acceptable carrier. The use of a compound of formula l in the preparation of a medicine against rheumatoid arthritis, osteoarthritis, osteoporosis, obstructive pulmonary disease, aberrant angiogenesis, multiple sclerosis, tumor metastases. |